The Milwaukee chapter invites you to attend “Rare Disease Therapies $500,000 and Higher: Plan Sponsors Take Warning!”, to be presented at and sponsored by Hays Companies in Wauwatosa, Wisconsin and via webinar.
With the removal of annual and lifetime dollar limits under the ACA, life preserving therapies for rare diseases not previously treatable or financially viable can carry six and seven figure annual costs. Their rarity stymies purchasing programs, effective PPO discounts and wellness programs. The financial risks to health plan sponsors, particularly those that self-insure, are significant. If it is an ongoing annual therapy, an unreserved future liability can be several millions of dollars. Risk management in the form of stop loss is being tested as never before, and increasingly applicable to plan sponsors of all sizes.
Ryan A. Siemers CEBS, CEBS-Compliant, ISCEBS Fellow
Aegis Risk LLC
Mr. Siemers is a principal at Aegis Risk LLC, focusing on medical stop loss and the risk management of catastrophic medical claimants. he has performed numerous medical stop-loss analyses for private and public employers throughout the United States. Mr. Siemers is the author of the annualAegis Risk Medical Stop-loss Premium Survey, done in conjunction with the International Society of Certified Employee Benefit Specialists (ISCEBS). With over 25 years of employee benefits experience, he has previously served as a health and welfare consultant and an underwriter prior to forming Aegis Risk. Mr. Siemers has a Bachelor of Arts degree in Economics from Baylor University and a Master's degree in Business Administration from the University of Florida. He earned the CEBS designation and is CEBS-Compliant and an ISCEBS Fellow. He is a member of the ISCBS Governing Council, currently serving as the Secretary/Treasurer of ISCEBS. He is a past president of the Capital Chapter.